Marcus Furch act as the CEO/CFO of Rodos Biotarget GmbH, a VC-funded company advancing drug delivery technologies and nanomedicines. He has advised, co-founded, and financed start-up companies in the life sciences. As former partner of a M&A boutique, advisor to private equity funds, as well as in permanent management positions at Fresenius SA, he was involved in merger and acquisition, licensing, corporate financing and venturing. He provided leadership to and managed interdisciplinary teams, e.g. in the acquisition of assets, in the advancement of portfolios comprising drug candidates from the development stage to clinical stage III, and in the establishment of manufacturing sites and legal entities. Prior to joining the industry, he was a management consultant in São Paulo providing services to enforce the competitiveness of chemical and pharmaceutical enterprises in Brazil. Based on this experience, he expanded his activities to the emerging markets of LATAM, MENA and China. As a research scientist, he worked in laboratories in Germany (Max-Planck Medical Research Heidelberg and Hannover Medical School), France (INSERM-CNRS), Spain (Universidad del Pais Vasco), and the US (TSRI). He received his advanced degree in chemistry and his PhD in biophysics and biochemistry from the University of Heidelberg. He also holds an executive MBA from the Maastricht University Business School (The Netherlands). He is a native German and speaks English, Spanish, Portuguese and French.